We just lately revealed a listing of Billionaire Ken Fisher’s 10 Healthcare Inventory Picks with Huge Upside Potential. On this article, we’re going to try the place AbbVie Inc. (NYSE:ABBV) stands towards different Billionaire Ken Fisher’s healthcare inventory picks with large upside potential.
The healthcare business, a vital part of world well-being and financial resilience, is present process vital adjustments. The business, which is assumed to account for greater than 10% of the world’s GDP, is about to enter a brand new period characterised by demographic shifts, digital innovation, and regulatory realignment. Stakeholders within the life sciences, diagnostics, and healthcare companies ecosystem face a conundrum as of 2025: stability is threatened by ongoing monetary pressure, rising operational complexity, and geopolitical dangers, regardless of the abundance of progress alternatives.
Healthcare earnings within the U.S. are nonetheless underneath strain. EBITDA as a proportion of nationwide well being spending has dropped by 150 foundation factors since 2019, which has a big impression on each payers and suppliers, in keeping with McKinsey. The World Well being Group tasks that there shall be a 10-million-person scarcity of healthcare employees worldwide by 2030, restricted reimbursement progress, and excessive inflationary costs. On the similar time, digital transformation has gained significance. In accordance with Deloitte, 90% of executives in world well being methods anticipate a sooner adoption of digital know-how, and over 70% of them intend to extend operational effectivity in 2025.
Synthetic intelligence (AI) is on the coronary heart of this alteration. AI, which was as soon as aspirational, is now a disruptive power that improves the whole lot from medical prognosis to hospital logistics. AI is seen by EU establishments as important to the modernization of public well being. The European Well being Information Area (EHDS), which shall be launched in 2025, and the European Fee’s 2024 AI Act goal to ensure that AI applied sciences are dependable and protected, whereas facilitating entry to high-quality, interoperable well being knowledge. These frameworks present sufferers and builders with authorized safety by simplifying legal responsibility requirements for flawed AI methods, along side the revised Product Legal responsibility Directive.
Nevertheless, points stay. Integrating AI into medical operations necessitates constant funding, cultural acceptance, and regulatory readability. Bias in knowledge, moral concerns, and the complexity of agentic AI options—instruments that work autonomously to carry out multi-step healthcare processes—require cautious administration. Regardless of these challenges, sensible functions are gaining traction: AI is presently utilized in early sepsis identification, breast most cancers screening, and pharmaceutical R&D, with the potential to shorten treatment growth timelines and enhance affected person outcomes.
In the meantime, current geopolitical developments are casting a shadow on world healthcare provide networks. In April 2025, President Donald Trump introduced substantial tariffs, together with a ten% baseline and focused taxes on medical gadgets, which could disrupt entry to important inputs like diagnostic instruments and protecting tools. “What Trump unveiled Wednesday is silly, unsuitable, arrogantly excessive, and ignorant trade-wise,” mentioned billionaire investor Ken Fisher in a harsh indictment of the proposal. Moreover, Morningstar and Fitch analysts warn of rising bills for hospitals, that are already coping with low margins and restricted pricing choices.
These adjustments—technological, legislative, and geopolitical—happen towards a backdrop of cautious optimism. Whereas GDP progress in the USA is predicted to drop from 2.7% in 2024 to 1.5% in 2025, the healthcare business stays robust. As AI integration deepens, coverage readability emerges, and funding cycles reset, the business could also be poised for a brand new period of progress.
To create our listing of Billionaire Ken Fisher’s 10 Healthcare Inventory Picks with Huge Upside Potential, we checked out Ken Fisher’s This autumn 2024 13F SEC filings to seek out healthcare shares in his portfolio. We then selected the ten shares with the very best upside potential based mostly on common analyst worth forecasts, as of the time of writing this text. The equities have been then sorted in ascending order of predicted upside. This technique highlights essentially the most promising healthcare investments in Fisher’s present portfolio. Moreover, hedge fund sentiment was additionally laid out for these shares, as of Insider Monkey’s This autumn 2024 database.
Why are we within the shares that hedge funds pile into? The reason being easy: our analysis has proven that we are able to outperform the market by imitating the highest inventory picks of the most effective hedge funds. Our quarterly e-newsletter’s technique selects 14 small-cap and large-cap shares each quarter and has returned 373.4% since Could 2014, beating its benchmark by 218 proportion factors (see extra particulars right here).
AbbVie Inc. (ABBV): Amongst Billionaire Ken Fisher’s Healthcare Inventory Picks with Huge Upside Potential
A pharmacist handing out a pharmaceutical drug to a affected person in a drug retailer or chemist.
Upside Potential: 24.48%
Variety of Hedge Fund Holders: 85
AbbVie Inc. (NYSE:ABBV) is a worldwide biopharmaceutical agency, based mostly in North Chicago, Illinois. Since its inception in 2012, AbbVie has targeted on discovering novel therapies to deal with severe well being ailments. The group works in a number of therapeutic areas, together with immunology, most cancers, neuroscience, eye care, virology, and aesthetics. AbbVie is properly acknowledged for its main therapies, together with Humira, Skyrizi, Rinvoq, Imbruvica, and Venclexta. It additionally sells Botox for each therapeutic and beauty functions, Vraylar for psychiatric points, and quite a lot of therapies for migraines and eye ailments.
AbbVie Inc. (NYSE:ABBV) reported adjusted earnings per share of $2.16 per share and whole internet income of $15.1 billion within the fourth quarter of 2024, led by a 22% improve in its ex-Humira platform. Regardless of challenges from the Medicare Half D reform and international trade implications, the corporate expects whole internet revenues of round $59 billion in 2025.
AbbVie Inc. (NYSE:ABBV) is continuous to construct its pipeline by way of selective acquisitions and inner innovation. In 2024, the corporate bought neuroscience specialist Cerevel Therapeutics, oncology-focused ImmunoGen, and Alzheimer’s therapeutic growth Aliada for greater than $20 billion. AbbVie anticipates incurring $248 million in milestone funds and R&D bills in 2025 because of these acquisitions, inflicting its adjusted revenue outlook to be revised.
Along with robust financials, AbbVie Inc. (NYSE:ABBV) is growing a number of late-stage medical initiatives in oncology, immunology, and neurology. Notably, the corporate is making ready for potential regulatory approvals of Teliso-V and Temab-A in lung and colorectal most cancers, in addition to additional investigations of Emraclidine in psychiatric issues and Tavapadon in Parkinson’s illness.
AbbVie Inc. (NYSE:ABBV) is a key holding in Ken Fisher’s inventory portfolio, demonstrating its robust progress potential and various pipeline. With a powerful product portfolio, lively medical growth, and strategic acquisitions, it’s well-positioned to take care of momentum and create long-term worth within the healthcare business.
General, ABBV ranks ninth on our listing of Billionaire Ken Fisher’s healthcare inventory picks with large upside potential. Whereas we acknowledge the potential of those firms, our conviction lies within the perception that some AI shares maintain higher promise for delivering larger returns, and doing so inside a shorter timeframe. There may be an AI inventory that went up because the starting of 2025, whereas well-liked AI shares misplaced round 25%. If you’re on the lookout for an AI inventory that’s extra promising than ABBV however that trades at lower than 5 occasions its earnings, try our report about this least expensive AI inventory.
READ NEXT: 20 Greatest AI Shares To Purchase Now and 30 Greatest Shares to Purchase Now In accordance with Billionaires.
Disclosure: None. This text is initially revealed at Insider Monkey.
